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Niemann-Pick C1 disease (NPC1) is a rare autosomal 
recessive lysosomal storage disease, which was 
separated from the sphinomyelinase-deficient NPCA 
and NPCB when cholesterol was found to be stored.1 No 
drugs for the disease are currently approved in the USA, 
although miglustat is approved in Europe. In The Lancet, 
Daniel Ory and colleagues2 report strong evidence that 
intrathecal delivery of hydroxypropyl-beta-cyclodextrin 
(HPBCD) slows the progression of NPC1. 
In this non-randomised, open-label, dose-escalation 
phase 1/2a study, 14 neurologically affected NPC1 
patients were given monthly intrathecal HPBCD doses 
ranging from 50 mg to 1200 mg. Three additional 
patients were treated every 2 weeks for 18 months. Ory 
and colleagues2 reported no major adverse events, and 
treated patients showed improved neurological severity 
scores compared with a historical cohort of 21 NPC1 
participants of similar age range, suggesting slowed 
disease progression. This rate of progression decreased 
as measured by a multimodal scale, especially for 
cognition and speech.  
Cyclodextrins are used to move cholesterol in or out 
of cell membranes.3 In 2001, Camargo and colleagues4 
reported a small but significant effect of HPBCD on 
slowing neurodegeneration in a mouse model of 
NPC1. When treatment was started earlier and at 
higher doses, HPBCD was found to be efficacious in 
extending survival.5 Intrathecal delivery to mouse 
and cat brains was shown to be quite effective in 
ameliorating the symptoms of the disease.2 Ory and 
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event, and those with medically managed acute 
coronary syndrome were excluded.
Despite the diagnostic value of PFT, over the past 
decade, RCTs have failed to show its role in guiding 
the choice of antiplatelet therapy. In turn, PFT has 
struggled to find a space in routine clinical practice. The 
experience from previous studies led to the design of the 
TROPICAL-ACS trial, the results of which now provide 
additional insights on how to use PFT to help select a 
P2Y12 inhibitor, thus suggesting a potential resurgence of 
a nearly abandoned instrument. Future research should 
build upon TROPICAL-ACS to help to define antiplatelet 
treatment approaches associated with optimal safety and 
efficacy performance profiles for the individual patient.
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colleagues’ work extends these studies to human 
beings.
The findings from Ory and colleagues’ study2 raise many 
questions. First, is the benefit only from desequestering 
cholesterol in the cell, allowing more normal cholesterol 
metabolism, or removal of excess cholesterol? Second, 
are there particular cells for which the therapy is most 
important? NPC has been termed juvenile Alzheimer’s, 
another disorder in which cholesterol metabolism is 
important and in which treatment with HPBCD in animal 
models has been beneficial.6 Both diseases share defects 
of autophagy and activation of microglia. Correction 
of cholesterol storage in these cells may attenuate the 
microglial activation, which seems to be a major initiator 
of autophagic and other destructive pathways causing 
neurodegeneration in NPC disease.7
Third, what is the fate of the cholesterol-laden 
HPBCD?  In one study,8 the HPBCD-cholesterol complex 
was slowly cleared while free HPBCD appeared in 
urine within 24 h.  Liu and colleagues5 found of nearly 
2 times increase in acidic sterol (ie, bile acids) output in 
faeces with HPBCD treatment. Would the cholesterol-
laden HPBCD increase lung storage of cholesterol as 
it passes through the pulmonary capillary bed? This 
could be important as, in mouse models, systemic 
delivery of HPBCD did not decrease cholesterol storage 
in the lung5,9 and might have made it worse. Pulmonary 
complications contribute to patient deaths, especially in 
patients with NPC2.
Better drugs and modes of delivery will certainly 
be developed. One can envision continuous infusion 
of HPBCD with a pump as is done with baclofen for 
spasticity of cerebral origin,10 and this therapy might 
also provide increased hope for babies born with NPC1. 
Whole exome sequencing has become very cheap and 
could replace biochemical tests for newborn screening, 
adding NPC1 and NPC2 to the panel. The early diagnosis 
accompanied by therapy started at pre-symptomatic 
stages of the disease would be expected to secure better 
efficacy. This possibility is particularly attractive for 
cerebellar dysfunction, as it largely anticipates the onset 
of symptoms. In the mouse, cerebellar morphogenic 
defects occur near birth and are demonstrated by a 
small cerebellum at 7 days postnatally.  These defects, 
which are likely to be responsible for the pronounced 
vulnerability of the cerebellum, are mostly rescued by 
the HPBCD administration during early post natal life.11
Because the full development and functional 
maturation of the human cerebellum encompasses 
several years of post natal life, with Purkinje cells 
reaching adult size only at age 7–9 years,12 there is 
a large temporal window for rescuing cholesterol 
dyshomoeostasis. Of course, the potential toxicity of 
such early therapy on the developing nervous system 
would need to be studied, but allowing cholesterol to be 
more available to many pathways in development might 
not be dangerous. The study by Ory and colleagues2 is 
a major advance in the treatment of this devastating 
disease and is to be applauded.
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